| Old Articles: <Older 17981-17990 Newer> |
|---|
 |
The Motley Fool
November 1, 2006 |
HouseValues Needs Renovation: Fool by Numbers The real estate lead-generator released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...   |
The Motley Fool
November 1, 2006
Matt Koppenheffer |
How to Survive a Bear Attack Stock market bears can be severely hazardous to your financial health, and if you plan to navigate the backwoods of the stock market, it helps to understand them. Not all bears -- stock market or otherwise -- are alike, and it's important to know the best response for each species. |
The Motley Fool
November 1, 2006
Alyce Lomax |
Is It Time for Time Warner? Time Warner's third quarter had some bright spots, but there are a few elements that some investors might not find too thrilling. |
The Motley Fool
November 1, 2006
Anders Bylund |
Foolish Forecast: TTM's Perfect Timing The printed circuit board manufacturer is ready to report third-quarter 2006 earnings -- here is what investors can expect to see. |
The Motley Fool
November 1, 2006
Ryan Fuhrmann |
CEC Seeing the Light CEC Entertainment and its Chuck E. Cheese restaurant chain just reported some impressive preliminary quarterly results, with stock option issues potentially coming to an end. Investors, take note. |
The Motley Fool
November 1, 2006 |
U.S. Steel Rolls On: Fool by Numbers The steel manufacturer released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 1, 2006 |
P&G's Razor-Sharp Q1: Fool by Numbers Proctor & Gamble released its first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 1, 2006
Brian Lawler |
Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note. |
The Motley Fool
November 1, 2006
Ryan Fuhrmann |
Skechers Sketches Out a Nice Quarter Skechers just posted some solid quarterly numbers, but one strong selling season does not make a trend. Investors, take note. |
The Motley Fool
November 1, 2006
Brian Lawler |
Waiting for CVT's Trial Results The biopharm reported third-quarter 2006 earnings that were mostly as expected. Investors are just awaiting the clinical trial results from the company's large phase 3 Merlin study testing its marketed angina drug, Ranexa. |
| <Older 17981-17990 Newer> Return to current articles. |
